Dermatol. praxi. 2013;7(4):166-169

Superficial candidiases and treatment options

doc.MUDr.Růžena Pánková, CSc.
Dermatovenerologická klinika 1. LF UK a VFN, Praha

Candidiasis is the most frequent mycosis with a number of different clinical presentations of varying severity. Superficial candidiases

include intertriginous candidiasis; mucosal candidiasis – oral, vulvar and vaginal; balanitis and balanoposthitis; paronychial candidiasis;

and chronic mucosal and cutaneous candidiasis. The clinical course is usually chronic and recurrent; however, there may be

candidiases with a severe, life-threatening course. The diagnosis should be established based on evaluation of history, clinical finding,

native microscopy, and culture result. Most Candida infections (more than 90%) are caused by five most commonly occurring species

– Candida albicans, Candida parapsilosis, Candida tropicalis, Candida glabrata and Candida krusei. A precondition for colonization

is the adherence of Candida species to the mucosal epithelium. The Candida C3d protein that binds to cell surface participates in

the adherence, as do proteolytic enzymes, toxins, and yeast phospholipase. The host susceptibility to colonization of the skin and

mucosae by yeast is contributed to by several factors simultaneously. Local treatment for superficial candidiases includes imidazoles,

triazoles, allylamines, and nystatin. Granulomatous and invasive forms of candidiases are treated locally and systemically with triazoles,

allylamines (terbinafine), echinocandins (caspofungin), and amphotericin B. The treatment involves elimination of associated

factors that promote the development of infection. For resistance purposes, the possibility of determination of yeast sensitivity to

antifungal drugs should be available.

Keywords: superficial candidiases, clinical precentation, treatment

Published: December 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pánková R. Superficial candidiases and treatment options. Dermatol. praxi. 2013;7(4):166-169.
Download citation

References

  1. Hay RJ, Moore MK. Mycology (p 1405-1506).chapter 31 in Rook's Textbook of Dermatology, Seventh Edition Edited by Tony Burns, Neil Cox Christopher Griffiths Copyright (C) 2004 by Blackwell Science Ltd. Go to original source...
  2. Mašata J, Jedličková A, a kol. Infekce v gynekologii a porodnictví. Maxdorf, Praha 2004.
  3. Staňková M, Marešová M, Vaništa J. Repetitorium infekčních nemocí. Praha: Triton 2008, http://www.tridistri.cz.
  4. Hamal P, Raclavský V, Svobodová L, et al. Současné možnosti antimykotické léčby invazivní kandidózy na jednotkách intenzivní péče. Klin Mikrobiol Infekc Lek 2010; 16(5): 164-170. Go to PubMed...
  5. Kuklová I, Kaštánková V, Pánková R, Binder T, Hrušková H. Souvislosti mykotických vulvovaginitid u žen vyšetřených na venerologické ambulanci I. kožní kliniky. Čs. Derm, 1997; 72: 134-136.
  6. Kuklová I. Vulvovaginální kandidóza. Referátový výběr z dermatovenerologie 2010; 52, Speciál II, s. 17-22.
  7. Kuklová I. Kožní mykózy. In Dermatovenerologie, dětská dermatologie a korektivní dermatologie. Kolektiv autorů. Trendy v medicíně. Triton: Praha 2006, www.tridistri.cz.
  8. Velčevský P, Kuklová I. Léčba sexuálně přenosných onemocnění. Čes-slov Derm 2008; 83: 123-136.
  9. Vosmík F, Skořepová M. Dermatomykózy. 1. vyd. Praha, Galén 1995; 140.
  10. Arenberger P, Jírová M. Onychomykózy. Trendy v medicíně 2001; 3: 56-60.
  11. Štork J, et al. Candidosis in Dermatovenerologie, Galén, Karolinum, 2008: 76-78.
  12. Kršek M. Endokrinologie in Interna, Čéška, R. a kol., 2010, Triton, Isbn. 978-80-7387-423-0, s. 318-370.
  13. Ahonen P, Myllarniemi S, Sipila I, et al. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990; 322: 1829-1836. Go to original source... Go to PubMed...
  14. Kuklová I. Sexuálně přenosná onemocnění. In: Weiss a kolektiv. Sexuologie. Praha, Grada 2010: 579-612.
  15. Meriluoto T, Halonen M, Pelto-Huikko M, et al. The autoimmune regulator: a key toward understanding the molecular pathogenesis of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Keio J Med 2001; 50: 225-239. Go to original source... Go to PubMed...
  16. Rubén López-Martínez, Candidosis, a new challenge. Clinics in Dermatology 2010; 28: 178-184. Go to original source... Go to PubMed...
  17. Skořepová M. Antimykotika z pohledu dermatologa. REMEDIA - farmakoterapeutický časopis, 1, 2002, www.remedia.cz.
  18. Slíva J, Votava M. Farmakologie. Praha: Triton 2010, http://www.tridistri.cz.




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.